Access

Brief Communications Arising

Nature 443, E5 (21 September 2006) | doi:10.1038/nature05218; Published online 20 September 2006

Open Innovation Challenges

naturejobs

Gene therapy: Is IL2RG oncogenic in T-cell development?

Karin Pike-Overzet1, Dick de Ridder3, Floor Weerkamp1, Miranda R. M. Baert1, Monique M. Verstegen2, Martijn H. Brugman2, Steven J. Howe3, Marcel J. T. Reinders2, Adrian J. Thrasher4, Gerard Wagemaker2, Jacques J. M. van Dongen1 & Frank J. T. Staal1

Top

Arising from: N.-B. Woods, V. Bottero, M. Schmidt, C. von Kalle & I. M. Verma Nature 440, 1123 (2006); see also communication from Thrasher et al.; Woods et al. reply

The gene IL2RG encodes the gamma-chain of the interleukin-2 receptor and is mutated in patients with X-linked severe combined immune deficiency (X-SCID). Woods et al.1 report the development of thymus tumours in a mouse model of X-SCID after correction by lentiviral overexpression of IL2RG and claim that these were caused by IL2RG itself. Here we find that retroviral overexpression of IL2RG in human CD34+ cells has no effect on T-cell development, whereas overexpression of the T-cell acute lymphoblastic leukaemia (T-ALL) oncogene LMO2 leads to severe abnormalities. Retroviral expression of IL2RG may therefore not be directly oncogenic — rather, the restoration of normal signalling by the interleukin-7 receptor to X-SCID precursor cells allows progression of T-cell development to stages that are permissive for the pro-leukaemic effects of ectopic LMO2.